KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2).

Ramez N Eskander, Bradley Corr, David Cibula, David S P Tan, Noelle Cloven, Eva Guerra, Kosei Hasegawa, Tashanna Myers, Benoit You, Vicky Makker, Flora Zagouri, Lilian T Gien, Michele Bartoletti, Adrianne Mallen, Linn Woelber, Simonetta Mocci, Kimberly Komatsubara, Long Ma, Nicoletta Colombo

Int J Gynecol Cancer 36(6) 102654

PMID41073155
PMCID-
DOI10.1016/j.ijgc.2025.102654
发表日期2025-10-10
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND: Patients with recurrent or metastatic endometrial cancer who have progressed on or after platinum-based chemotherapy and PD-(L)1 inhibitor therapy have limited treatment options and a poor prognosis. Sacituzumab govitecan is a trophoblast cell-surface antigen 2-directed antibody-drug conjugate approved for certain types of breast cancer. In the phase II TROPiCS-03 trial, sacituzumab govitecan demonstrated encouraging efficacy and manageable safety in heavily pretreated patients with advanced or metastatic endometrial cancer. PRIMARY OBJECTIVE(S): The ASCENT-GYN-01 trial aims to assess the efficacy and safety of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer who have received platinum-based chemotherapy and PD-(L)1 inhibitor therapy. The primary objective is to compare the effect of sacituzumab govitecan versus treatment of the physician's choice on progression-free survival, assessed by blinded independent central review, and on overall survival. STUDY HYPOTHESIS: Patients with pretreated recurrent or persistent endometrial cancer will have improved progression-free survival and overall survival with sacituzumab govitecan compared with treatment of the physician's choice. TRIAL DESIGN: ASCENT-GYN-01 (ClinicalTrials.gov identifier NCT06486441) is a randomized, open-label, global phase III study. Patients will be randomized in a 1:1 ratio to receive sacituzumab govitecan or treatment of the physician's choice (doxorubicin or paclitaxel). MAJOR INCLUSION/EXCLUSION CRITERIA: Patients aged 18 years and older with documented evidence of recurrent or persistent endometrial cancer (endometrial carcinoma or carcinosarcoma) will be enrolled. Up to 3 prior lines of systemic therapy for endometrial cancer are allowed, including platinum-based chemotherapy and PD-(L)1 inhibitor therapy, either in combination or separately. Key exclusion criteria include uterine leiomyosarcoma or endometrial stromal sarcomas and prior treatment with a trophoblast cell-surface antigen 2-directed antibody-drug conjugate or topoisomerase I inhibitor. PRIMARY ENDPOINT(S): Dual primary endpoints are progression-free survival assessed by blinded independent central review and overall survival. SAMPLE SIZE: Approximately 640 patients. ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS: June 2029. TRIAL REGISTRATION: NCT06486441; GOG-3104; ENGOT-en26; APGOT-EN2.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。